Collectively, these data demonstrate that ME treatment increases the sensitivity of ovarian cancer cells to cisplatin by suppressing HSP90AB1 expression, thereby inhibiting the proliferation, invasion, and migration of ovarian cancer cells. This evidence concerns the gene HSP90AB1 and ovarian carcinoma.